{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:19:04Z","timestamp":1791908344860,"version":"4.3.4"},"reference-count":44,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"College of Medicine, National Yang Ming Chiao Tung University"},{"name":"Medical AI Development Center, Taipei Veterans General Hospital"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Sugemalimab demonstrated clinical efficacy in the GEMSTONE-303 trial, but its cost-effectiveness remains unclear. This study aims to evaluate the cost-effectiveness of sugemalimab in combination with chemotherapy (CAPOX) as a first-line treatment for patients with advanced or metastatic gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma, compared to chemotherapy alone, from the perspective of Taiwan\u2019s healthcare payer. Methods: A partitioned survival model was developed to simulate outcomes over a 40-year time horizon, and model parameters were derived from GEMSTONE-303 and the wider literature. Health benefits were measured in quality-adjusted life-years (QALYs), and only direct medical costs were included, with both discounted at an annual rate of 3%. The willingness-to-pay threshold was set at three times the 2024 GDP per capita. Deterministic and probabilistic sensitivity analyses were conducted alongside scenario analyses. Results: Compared to capecitabine and oxaliplatin (CAPOX) alone, adding sugemalimab yielded an incremental gain of 0.39 QALYs at an additional cost of USD 47,020, resulting in an incremental net monetary benefit of \u2212USD 7478. Conclusions: Sugemalimab plus CAPOX is not cost-effective for advanced or metastatic G\/GEJ adenocarcinoma from the Taiwan payer\u2019s perspective. Achieving cost-effectiveness would require a 20\u201330% price reduction for sugemalimab (to USD 1204\u2013USD 1376 per 600 mg), assuming first-line therapy is administered for the median treatment duration observed in the GEMSTONE-303 trial. If reimbursement continued until disease progression, a reduction of approximately 68% would be required (USD 550 per 600 mg).<\/jats:p>","DOI":"10.3390\/cancers17193171","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T08:21:51Z","timestamp":1759220511000},"page":"3171","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Cost-Effectiveness of Sugemalimab Plus CAPOX in Treating Advanced Gastric Cancer: Analysis from the GEMSTONE-303 Trial"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3337-2586","authenticated-orcid":false,"given":"Chen-Han","family":"Chueh","sequence":"first","affiliation":[{"name":"Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ming","family":"Huang","sequence":"additional","affiliation":[{"name":"Institute of Health and Welfare Policy, College of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan"},{"name":"Medical AI Development Center, Taipei Veterans General Hospital, Taipei 11217, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4057-3662","authenticated-orcid":false,"given":"Ming-Yu","family":"Hong","sequence":"additional","affiliation":[{"name":"Institute of Health and Welfare Policy, College of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-7217","authenticated-orcid":false,"given":"Yi-Wen","family":"Tsai","sequence":"additional","affiliation":[{"name":"Institute of Health and Welfare Policy, College of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan"},{"name":"Medical AI Development Center, Taipei Veterans General Hospital, Taipei 11217, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Jung","family":"Chiang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Taipei Veterans General Hospital, Taipei 11217, Taiwan"},{"name":"School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan"},{"name":"National Institute of Cancer Research, National Health Research Institutes, Miaoli County 35053, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao-Ling","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Health and Welfare Policy, College of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","unstructured":"(2025, April 20). GBD Compare. Available online: http:\/\/vizhub.healthdata.org\/gbd-compare."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Qin, N., Fan, Y., Yang, T., Yang, Z., and Fan, D. (2025). The Burden of Gastric Cancer and Possible Risk Factors from 1990 to 2021, and Projections until 2035: Findings from the Global Burden of Disease Study 2021. Biomark. Res., 13.","DOI":"10.1186\/s40364-024-00720-8"},{"key":"ref_4","unstructured":"(2025, July 21). Guidelines Detail. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1434."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1001\/jama.2025.0630","article-title":"PD-1 or PD-L1\u2014A Difference That Makes No Difference?","volume":"333","author":"Klempner","year":"2025","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-Line Nivolumab plus Chemotherapy versus Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1200\/JCO.23.01601","article-title":"First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial","volume":"42","author":"Janjigian","year":"2024","journal-title":"JCO"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1200\/JCO.2024.42.16_suppl.4045","article-title":"Pembrolizumab (Pembro) + Chemotherapy (Chemo) for Advanced HER2-Negative Gastric or Gastroesophageal Junction (G\/GEJ) Cancer: Updated Results from the KEYNOTE-859 Study","volume":"42","author":"Rha","year":"2024","journal-title":"JCO"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus Chemotherapy versus Placebo plus Chemotherapy for HER2-Negative Advanced Gastric Cancer (KEYNOTE-859): A Multicentre, Randomised, Double-Blind, Phase 3 Trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e078876","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus Chemotherapy versus Placebo plus Chemotherapy as First Line Treatment for Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma: RATIONALE-305 Randomised, Double Blind, Phase 3 Trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"ref_12","unstructured":"Lordick, F., Candia Montero, L., Castelo-Branco, L., Pentheroudakis, G., Sessa, C., and Smyth, E.C. (2025, August 11). ESMO Gastric Cancer Living Guideline v1.4. Available online: https:\/\/www.esmo.org\/guidelines\/living-guidelines\/esmo-living-guideline-gastric-cancer."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1470-2045(21)00630-6","article-title":"Sugemalimab versus Placebo after Concurrent or Sequential Chemoradiotherapy in Patients with Locally Advanced, Unresectable, Stage III Non-Small-Cell Lung Cancer in China (GEMSTONE-301): Interim Results of a Randomised, Double-Blind, Multicentre, Phase 3 Trial","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S1470-2045(21)00650-1","article-title":"Sugemalimab versus Placebo, in Combination with Platinum-Based Chemotherapy, as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (GEMSTONE-302): Interim and Final Analyses of a Double-Blind, Randomised, Phase 3 Clinical Trial","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S1470-2045(25)00198-6","article-title":"Sugemalimab versus Placebo, in Combination with Platinum-Based Chemotherapy, as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (GEMSTONE-302): 4-Year Outcomes from a Double-Blind, Randomised, Phase 3 Trial","volume":"26","author":"Zhou","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41591-024-02797-y","article-title":"First-Line Sugemalimab with Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma: A Randomized Phase 3 Study","volume":"30","author":"Li","year":"2024","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Zhang, X., Wang, J., Wang, G., Zhang, Y., Fan, Q., Lu, C., Hu, C., Sun, M., Wan, Y., and Sun, S. (2025). First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial. JAMA.","DOI":"10.1001\/jama.2024.28463"},{"key":"ref_18","unstructured":"(2025, September 18). Cejemly|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cejemly."},{"key":"ref_19","unstructured":"(2025, July 21). Sugemalimab Approved to Treat Adult Patients with Non-Small Cell Lung Cancer, Available online: https:\/\/www.gov.uk\/government\/news\/sugemalimab-approved-to-treat-adult-patients-with-non-small-cell-lung-cancer."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40265-022-01693-4","article-title":"Sugemalimab: First Approval","volume":"82","author":"Dhillon","year":"2022","journal-title":"Drugs"},{"key":"ref_21","unstructured":"(2025, July 21). CStone Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer-CStone Pharmaceuticals. Available online: https:\/\/www.cstonepharma.com\/en\/html\/news\/3668.html."},{"key":"ref_22","unstructured":"(2025, September 18). Sugemalimab 600 mg (20.0 mL)\u2014Yaozh. Available online: https:\/\/db.yaozh.com\/pijian\/bJmWaWllbmZplWRilJaanDkwMzli.html."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Tang, L., Zhu, L., Zhan, S., Chen, Y., and Feng, P.-F. (2025). Cost-Effectiveness Analysis of Sugemalimab Combined with Chemotherapy as First-Line Treatment for Advanced Gastric Cancer. Front. Public Health, 13.","DOI":"10.3389\/fpubh.2025.1620663"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Zhang, Y., He, Y., Chen, R., and You, M. (2025). Cost-Effective Analysis of Sugemalimab plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma with PD-L1 CPS \u2265 5. Front. Public Health, 13.","DOI":"10.3389\/fpubh.2025.1604372"},{"key":"ref_25","unstructured":"(2025, July 28). Statistical Tables, Available online: https:\/\/eng.stat.gov.tw\/cp.aspx?n=2334."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.1016\/j.jval.2024.10.1116","article-title":"EE836 Cost-Effectiveness of Zolbetuximab Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Adenocarcinoma in Taiwan","volume":"27","author":"Huang","year":"2024","journal-title":"Value Health"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Chen, K.-A., Huang, W.-M., Chen, E.Y.-T., Ho, P.-K., Chueh, C.-H., Wen, Y.-W., Chen, M.-H., Chiang, N.-J., and Tsai, Y.-W. (2024). Cost-Effectiveness of Ivosidenib versus Chemotherapy for Previously Treated IDH1-Mutant Advanced Intrahepatic Cholangiocarcinoma in Taiwan. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12362-y"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40273-022-01227-6","article-title":"Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy","volume":"41","author":"Chueh","year":"2023","journal-title":"PharmacoEconomics"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12962-023-00473-5","article-title":"Cost-Effectiveness of Pemigatinib as a Second-Line Treatment for Advanced Intrahepatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 Fusions in Taiwan: From the Evidence of the Phase II Trial and the Perspective of Taiwan\u2019s National Health Insurance Administration","volume":"21","author":"Chen","year":"2023","journal-title":"Cost Eff. Resour. Alloc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Filipovi\u0107-Pierucci, A., Zarca, K., and Durand-Zaleski, I. (2017). Markov Models for Health Economic Evaluations: The R Package Heemod. arXiv.","DOI":"10.1016\/j.jval.2016.09.133"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Guyot, P., Ades, A., Ouwens, M.J., and Welton, N.J. (2012). Enhanced Secondary Analysis of Survival Data: Reconstructing the Data from Published Kaplan-Meier Survival Curves. BMC Med. Res. Methodol., 12.","DOI":"10.1186\/1471-2288-12-9"},{"key":"ref_34","unstructured":"Automeris (2025, July 28). Io: Computer Vision Assisted Data Extraction from Charts Using WebPlotDigitizer. Available online: https:\/\/automeris.io\/."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Liu, N., Zhou, Y., and Lee, J.J. (2021). IPDfromKM: Reconstruct Individual Patient Data from Published Kaplan-Meier Survival Curves. BMC Med. Res. Methodol., 21.","DOI":"10.1186\/s12874-021-01308-8"},{"key":"ref_36","unstructured":"Latimer, N. (2011). Nice Dsu Technical Support Document 14: Survival Analysis for Economic Evaluations Alongside Clinical Trials\u2014Extrapolation with Patient-Level Data, Decision Support Unit."},{"key":"ref_37","unstructured":"(2025, July 17). Drugdataexpy. Available online: https:\/\/data.yaozh.com\/."},{"key":"ref_38","unstructured":"Australian Government Department of Health and Aged Care, Pharmaceutical Benefits Scheme (PBS) (2025, July 21). Nivolumab (HER-2-Neg Gastric Cancer, Gastroesophageal Junction Cancer or Oesophageal Adenocarcinoma): Injection Concentrate for I.V. Infusion 40 Mg in 4 mL, Injection Concentrate for I.V. Infusion 100 Mg in 10 mL; OPDIVO\u00ae, Available online: https:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2022-03\/nivolumab-her-2-neg-gastric-cancer-gastroesophageal-junction-cancer."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Cai, H., Xu, B., Li, N., Zheng, B., Zheng, Z., and Liu, M. (2021). Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.732912"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1477-7525-6-84","article-title":"Health State Utilities for Non Small Cell Lung Cancer","volume":"6","author":"Nafees","year":"2008","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_41","unstructured":"Taiwan Center for Drug Evaluation (2025, August 08). Methodology Guidelines for Health Technology Assessment. Available online: https:\/\/www.cde.org.tw\/hta\/1444\/1834\/2155\/12989\/."},{"key":"ref_42","unstructured":"National Health Insurance Administration, Ministry of Health and Welfare (2025, August 12). Settlement and Estimated Point Value, Available online: https:\/\/www.nhi.gov.tw\/ch\/cp-5773-4d180-2767-1.html."},{"key":"ref_43","unstructured":"(2025, July 28). Exchange Rates of TWD and Major Trading Partner Currencies Versus USD Over Selected Periods, Available online: https:\/\/cpx.cbc.gov.tw\/Range\/RangeSelect?pxfilename=BP01Y01.px."},{"key":"ref_44","unstructured":"(2025, August 17). CBC Statistical Database, Available online: https:\/\/cpx.cbc.gov.tw\/Data\/DataMain\/?pxfilename=BP06Y01en.px."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/19\/3171\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T08:34:19Z","timestamp":1759221259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/19\/3171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":44,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["cancers17193171"],"URL":"https:\/\/doi.org\/10.3390\/cancers17193171","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]}}}